Scientists have discovered a new synthetic drug that is effective in treating urinary tract infections that resist antibiotics, where the new drug can face bacteria such as coli -producing an enzyme that dismantles commonly used antibiotics such as penicillin, and the drug may be available in the United States of America by next year.
The experimental antibiotics package appears to be a new alternative for doctors treating persistent urinary tract infections, according to the “Health” website.
According to a recent article in the American Medical Association Journal, the new class of medications, CEFEPIME and Entezobactam, outperformed a reliable antibiotic system in the treatment of complex urinary tract infection.
In comparison to the approximately six out of ten patients treated with an existing combination of antibiotics, nearly eight out of every ten patients of infection were totally cleared by CEFEPIME/Entezobactam.
Based on these findings, the French company ALLLCRA Therapeutics plans to request the US Food and Drug Administration’s permission early next year.
The researchers said that the US Food and Drug Administration has quickly tracked the drug for approval as a qualified product for infectious diseases.
The team is specifically created to treat germs like E. coli, which has evolved the ability to produce an enzyme that breaks down widely used antibiotics like penicillin, rendering them useless.
The infection caused by the bacteria that produce this enzyme, which is called ESBL, has increased by more than 50 % between 2012 and 2017, according to the Centers for Disease Control and Prevention in the United States.
The Disease Control Center estimated in its 2019 report that these bacteria contributed to more than 197,000 hospital admissions and 9100 fatalities in 2017, classifying them as a “severe” danger to antibiotic resistance.
developing a novel medication to treat urinary tract infections that are antibiotic-resistant
About Author
